PharmExec Blog

Investment Pros Remain Bullish on Orphans

 An illustrious panel of investment professionals spoke optimistically on the orphan disease space in spite of concerns surrounding escalating drug prices in specialty pharmaceuticals.

The group consisting of executives from investment banks, hedge funds, venture capital firms and biopharma companies spoke to the National Organization for Rare Disease (NORD) at its s Rare Diseases and Orphan Products Breakthrough Summit in Alexandria, Virginia on Wednesday last week. Read More »

Posted in Orphan Drugs, pricing | Tagged , , | Leave a comment

Expanded Access: Myths, Truth and Behavior

Not all companies are big, small companies are scared, and myths drive behavior, stated Kay Holcombe, Senior Vice President, Science Policy at Biotechnology Industry Organization (BIO). Read More »

Posted in FDA, Orphan Drugs | Leave a comment

Pharma Feels Impact of US Tax Inversion Legislation

The recent termination of AbbVie’s deal to acquire Shire has “jolted the industry out of its reverie” by becoming pharma’s first major casualty of new US tax inversion legislation,  says research and consulting firm GlobalData.

Read More »

Posted in Deals, Europe, Global, Strategy | Tagged , , , | Leave a comment

US Healthcare Reform: A Pharm Exec Digest Special

This month’s special issue of Pharm Exec Global Digest looks atUS_healthcare_reform_special

  • Dealing with the “side effects” of Obamacare
  • The “value” of Rxs under Obamacare
  • The escalating cost of US oncology care
  • And more…

Click here to read the issue.

Posted in Global, healthcare, Regulatory | Tagged , , , | Leave a comment

The Shrinking CMO Industry

By Jim Miller.

Exits from the CMO industry are a more recent development that seems to be picking up momentum. Examples of CMOs leaving the industry in the past year include the contract manufacturing units of Bayer and Boehringer-Ingelheim; Pharmalucence; and SCM Pharma. There have been two principal drivers of these developments: growing demand for captive manufacturing capacity and regulatory compliance difficulties. Read More »

Posted in Guest Blog, Manufacturing, Strategy | Tagged , | Leave a comment
  • Categories

  • Meta